[Procalcitonin in invasive candidosis]

Area of Science:

• Critical Care Medicine
• Infectious Diseases
• Clinical Diagnostics

Background:

• Accurate diagnosis of severe infections in intensive care units (ICUs) is crucial for patient management.
• Procalcitonin is a biomarker often used to indicate bacterial infections.
• The role of procalcitonin in diagnosing invasive fungal infections, specifically candidosis, requires further investigation.

Purpose of the Study:

• To evaluate the utility of serum procalcitonin measurements in diagnosing invasive candidosis in ICU patients.
• To determine if procalcitonin levels correlate with the presence and severity of candidosis.
• To assess the prognostic value of procalcitonin in this patient population.

Main Methods:

• A prospective study was conducted with 52 patients admitted to an intensive care unit.
• Serum procalcitonin levels were measured on days 1, 3, and 5 of the study.
• Patients were monitored for confirmed or probable cases of invasive candidosis.

Main Results:

• Procalcitonin levels were significantly elevated in patients with confirmed and probable invasive candidosis compared to those without.
• The study indicated a correlation between increased procalcitonin and the diagnosis of candidosis.
• Procalcitonin demonstrated a potential prognostic value in ICU patients with suspected invasive fungal infections.

Conclusions:

• Elevated procalcitonin levels in ICU patients should prompt consideration of invasive candidosis, not solely bacterial infections.
• Serum procalcitonin is a valuable biomarker for aiding the diagnosis of invasive candidosis in critical care settings.
• This finding supports the use of procalcitonin as part of the diagnostic workup for severe fungal infections in ICUs.